JPRN-C000000281已完成1 期
Phase I/II Study of Docetaxel and S-1 Combination Therapy for Advanced Non-small Cell Lung Cancer - Phase I/II Study of Docetaxel and S-1 Combination Therapy for Advanced Non-small Cell Lung Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Serious infectious disease 2)Patient receiving flucytosine 3)Apparent ineterstitial pneumonia or pulmonary fibrosis 4)Medical history of allergy or hypersensitivity reactions to S-1 or any drug containing polysorbate 80 5)Edema need for treatment 6)Pleural or pericardial effusion requiring treatment 7)Patient intermittent oxygen supply 8)Serious concomitant disease 9)Cardiac infarction within 6 month 10)Supra vena cava syndrome patient 11)Pregnant or lactation women, or women with known or suspected pregnancy. 12)Man who wont let to pregnancy 13)Clinical symptom of brain metastases 14)Medical history of serious allergy reactions to any drug 15)Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
2 期
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerMetastatic gastric cancer (Advanced or recurrent gastric cancer)JPRN-C000000103Hiroshima Cancer Therapy Development Organization (HiCTDO)50
已完成
3 期
A Phase III Study of Docetaxel and S-1 versus S-1 in the Treatment of Advanced Gastric CancerGastric CancerJPRN-C000000251Japan Clinical Cancer Research Organization628
已完成
不适用
A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric CancerGastric CancerJPRN-UMIN000010337Japan Clinical Cancer Reseach Organization (JACCRO)1,100
已完成
2 期
Phase II Study of Docetaxel and TS-1 Combination Therapy for Outpatients with Relapsed or Refractory Non-small Cell Lung cancerRelapsed or Refractory Non-small Cell Lung CancerJPRN-UMIN000000501Outpatient Oncology Unit Kyoto University Hospital40
暂停
2 期
A Phase II trial of S-1 and Docetaxel followed by FEC as neoadjuvant chemotherapy for primary breast cancerBreast CancerJPRN-UMIN000005100Keio University School of Medicine40